Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C
- 1 May 1998
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 32 (5) , 454-461
- https://doi.org/10.1046/j.1365-2559.1998.00413.x
Abstract
To evaluate the usefulness of easily assessable morphological parameters in liver biopsies in order to predict efficacy of interferon-α (IFN) treatment in patients with chronic hepatitis C. Inflammatory activity and fibrosis (according to Scheuer), and the hepatic iron content (according to Rowe and DiBisceglie) were assessed in pre-treatment liver biopsies of 73 de novo patients with chronic hepatitis C. Furthermore the presence of fat, lymphoid aggregates, and bile duct lesions was evaluated. With respect to IFN therapy patients were classified as responders alanine aminotransferase (ALT) normal and negative hepatitis C virus (HCV) RNA in serum at the end of treatment, n = 33) or non-responders (n = 40). Non-responders had more advanced fibrosis (P = 0.0001) and more extensive iron storage (P = 0.0008) than responders. In contrast absence of stainable iron was frequently (46%) associated with sustained response. Absence of fat droplets in hepatocytes was associated with response (P = 0.0001). Stepwise logistic regression analysis indicated that the stage of fibrosis, the hepatic iron grade, and the presence or absence of fat were independent predictors of response. Liver biopsy provides useful information for selection of patients with hepatitis C for IFN therapy.Keywords
This publication has 32 references indexed in Scilit:
- Dose increase augments response rate to interferon-α in chronic hepatitis CDigestive Diseases and Sciences, 1996
- Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitisPublished by Elsevier ,1995
- Response to interferon α therapy is influenced by the iron content of the liverJournal of Hepatology, 1994
- Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis CThe Journal of Pediatrics, 1994
- An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis CJournal of Hepatology, 1993
- Classification of chronic viral hepatitis: a need for reassessmentPublished by Elsevier ,1991
- Hepatitis B virus infection markers in genetic haemochromatosisJournal of Hepatology, 1991
- Recombinant Interferon Alfa Therapy for Chronic Hepatitis CNew England Journal of Medicine, 1989
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989
- Hepatocellular transferrin receptor expression in secondary siderosisLiver International, 1989